Related Experiment Video
Updated: Aug 7, 2025
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
Anna Maria Frustaci1, Marina Deodato1, Giulia Zamprogna1
1ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Piazza Ospedale Maggiore 3, 20162 Milano, Italy.
Abstract:
Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatment. In a head-to-head comparison of two phase III trials, both acalabrutinib and zanubrutinib demonstrated a lower incidence of adverse events in respect to ibrutinib. Nevertheless, resistance mutations remain a concern with continuous therapy and were demonstrated with both first- and next-generation covalent inhibitors. Reversible inhibitors showed efficacy independently of previous treatment and the presence of BTK mutations. Other strategies are currently under development in CLL, especially for high-risk patients, and include BTK inhibitor combinations with BCl2 inhibitors with or without anti-CD20 monoclonal antibodies. Finally, new mechanisms for BTK inhibition are under investigations in patients progressing with both covalent and non-covalent BTK and BCl2 inhibitors. Here we summarize and discuss results from main experiences on irreversible and reversable BTK inhibitors in CLL.
Insights
Newer Bruton's tyrosine kinase (BTK) inhibitors like acalabrutinib and zanubrutinib offer improved safety over ibrutinib for chronic lymphocytic leukemia (CLL) treatment. However, resistance remains a challenge, prompting research into novel therapies and combinations.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Ibrutinib significantly improved chronic lymphocytic leukemia (CLL) treatment outcomes, demonstrating long-term efficacy and safety.
- Emergence of next-generation Bruton's tyrosine kinase (BTK) inhibitors aims to mitigate toxicity and resistance associated with continuous ibrutinib therapy.
- Resistance mutations to covalent BTK inhibitors, including first- and next-generation drugs, are a persistent clinical concern in CLL management.
Purpose of the Study:
- To review and discuss the clinical experiences with irreversible and reversible BTK inhibitors in the treatment of CLL.
- To compare the safety and efficacy profiles of next-generation BTK inhibitors against ibrutinib.
- To explore emerging therapeutic strategies for CLL, particularly for high-risk patient populations.
Main Methods:
- Review of Phase III clinical trial data comparing acalabrutinib and zanubrutinib with ibrutinib.
- Analysis of studies investigating resistance mechanisms to covalent BTK inhibitors.
- Examination of research on reversible BTK inhibitors and novel combination therapies in CLL.
Main Results:
- Acalabrutinib and zanubrutinib showed a lower incidence of adverse events compared to ibrutinib in head-to-head trials.
- Resistance mutations are observed with both first- and next-generation covalent BTK inhibitors, indicating a need for alternative strategies.
- Reversible BTK inhibitors demonstrated efficacy irrespective of prior treatment or existing BTK mutations.
Conclusions:
- Next-generation BTK inhibitors offer improved safety profiles for CLL patients compared to ibrutinib.
- Addressing BTK inhibitor resistance is crucial, necessitating the investigation of novel agents and combination therapies, including BCL2 inhibitors and anti-CD20 antibodies.
- Ongoing research focuses on new BTK inhibition mechanisms for patients progressing on existing therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF